Johnson & Johnson stock (NYSE: JNJ) closed Friday’s bell at 234.34 and ended the day on the greener side of the spectrum, rising 1.13% and surging 2.61 points. The leading pharmaceutical giant has been on the front foot in 2026 by sustainably scaling up in the charts. JNJ has risen more than 13% year-to-date, rewarding traders with double-digit gains who took an entry position in early 2026. Johnson & Johnson has a string of medicine launches up until 2027, and could gain from the US Food and Drug Administration’s (FDA) approval.
After reaching a 52-week high of $251, Johnson & Johnson stock slid in the charts to the $234 level. Its price has remained rangebound since April, with buying activity cooling down across the medical sector. The piling up of lawsuits against the company is also among the reasons why investors are skipping JNJ. The medicine giant is fighting several cases across the US, keeping most of its legal team in defensive mode.
Also Read: Google Stock Gets ‘Firm Buy’ Rating From Goldman Sachs, See New Target
Johnson & Johnson Stock (JNJ) New Price Target by Leerink Partners
David Risinger, the Senior Research Analyst at Leerink Partners, upgraded his ‘hold’ call to ‘buy’ in mid-May. The analyst wrote in a note to clients that Johnson & Johnson is still undervalued and has the potential to surge hereon. He kept the rating for JNJ as ‘Outperform’ and cited the accelerating growth prospects driven by a wave of new drug launches.
According to the latest and revised price prediction, Johnson & Johnson stock is projected to reach a target of $265. That’s another $31 profit per share, and is stellar gains for traders who hold JNJ in their portfolio. If the price prediction turns out to be accurate, traders can turn $1,000 into $1,130. That’s an uptick and return on investment (ROI) of approximately 13% from its current price of $234.